Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C4 | P17516 | 1/20 | 0.69 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.69 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.69 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.69 |
| ▸ | LTC4S | Q16873 | 1/20 | 0.68 |
| ▸ | THRA | P10827 | 1/20 | 0.66 |
| ▸ | MAPT | P10636 | 4/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.58 |
| ▸ | ATM | Q13315 | 1/20 | 0.58 |
| ▸ | NPC1 | O15118 | 2/20 | 0.57 |
| ▸ | RAB9A | P51151 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 5/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | PYGL | P06737 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29472407 | 1.00 | AKR1C4 (0.69) | AKR1C4AKR1C3AKR1C2AKR1C1LTC4S | |
| SCHEMBL14418381 | 0.96 | AKR1C4 (0.64) | AKR1C4AKR1C3AKR1C2AKR1C1LTC4S | |
| SCHEMBL14413319 | 0.93 | LTC4S (0.65) | AKR1C4AKR1C3AKR1C2AKR1C1LTC4S | |
| SCHEMBL14583210 | 0.85 | LTC4S (0.64) | AKR1C4AKR1C3AKR1C2AKR1C1LTC4S | |
| SCHEMBL7126670 | 0.85 | PYGL (0.63) | AKR1C4AKR1C3AKR1C2AKR1C1THRA | |
| SCHEMBL6352508 | 0.84 | AKR1C2 (0.70) | AKR1C4AKR1C3AKR1C2AKR1C1MAPT | |
| SCHEMBL4092971 | 0.84 | KMT2A (0.71) | AKR1C4AKR1C3AKR1C2AKR1C1MAPT | |
| SCHEMBL14075422 | 0.82 | LTC4S (1.00) | AKR1C4AKR1C3AKR1C2AKR1C1LTC4S | |
| SCHEMBL2271993 | 0.81 | ALDH1A1 (0.61) | AKR1C4AKR1C3AKR1C2AKR1C1THRA | |
| SCHEMBL14087681 | 0.80 | LTC4S (0.75) | AKR1C4AKR1C3AKR1C2AKR1C1LTC4S |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240167107-A1 | COMPOSITION AND METHOD FOR NUCLEIC ACID DETECTION | APTITUDE MEDICAL SYSTEMS, INC. (US) | 2024-05-23 | — | — | US | claimed |
| US-7264932-B2 | Nuclease inhibitor cocktail | APPLERA CORPORATION (US) | 2007-09-04 | — | — | US | claimed |
| US-20050014169-A1 | Nuclease inhibitor cocktail | AMBION, INC. | 2005-01-20 | — | — | US | claimed |
| US-20240167107-A1 | COMPOSITION AND METHOD FOR NUCLEIC ACID DETECTION | APTITUDE MEDICAL SYSTEMS, INC. (US) | 2024-05-23 | — | — | US | disclosed |
| US-20170281649-A1 | COMPOUNDS AND THERAPEUTIC USES | UNITY BIOTECHNOLOGY, INC. | 2017-10-05 | — | — | US | disclosed |
| US-20110218155-A1 | CHEMICAL MODULATORS OF PRO-APOPTOTIC BAX AND BCL-2 POLYPEPTIDES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2011-09-08 | — | — | US | disclosed |
| WO-2008157747-A1 | USE OF INHIBITION OF EXONUCLEASE 1 IN METHODS FOR THERAPY AND DIAGNOSTIC OF NEURODEGENERATIVE DISEASES, EYE DISEASES, AND MITOCHONDRIAL DISORDERS | THE JACKSON LABORATORY (US) | 2008-12-24 | — | — | WO | disclosed |
| US-7429677-B2 | Small molecule entry inhibitors | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2008-09-30 | — | — | US | disclosed |
| US-7429677-B2 | Small molecule entry inhibitors | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2008-09-30 | — | — | US | disclosed |
| US-7264932-B2 | Nuclease inhibitor cocktail | APPLERA CORPORATION (US) | 2007-09-04 | — | — | US | disclosed |
| WO-2005083081-A1 | IMPROVED NUCLEASE INHIBITOR COCKTAIL | AMBION, INC. (US) | 2005-09-09 | — | — | WO | disclosed |
| US-20050014169-A1 | Nuclease inhibitor cocktail | AMBION, INC. | 2005-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170281649-A1 | COMPOUNDS AND THERAPEUTIC USES | TP53, NQO1, SHMT2 | AKR1C4 3122/4885AKR1C3 2701/4885AKR1C2 2585/4885 |
| US-20110218155-A1 | CHEMICAL MODULATORS OF PRO-APOPTOTIC BAX AND BCL-2 POLYPEPTIDES | BAX, BCL2, BCL2L1 | AKR1C4 4344/4885AKR1C3 4174/4885AKR1C2 3788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.